Definium Therapeutics (DFTX) Profit After Tax (2019 - 2026)
Definium Therapeutics (DFTX) reported Profit After Tax of -$77.1 million for Q1 2026, down 230.21% year-over-year from $59.2 million in Q1 2025, and down 52.86% on a QoQ basis from -$50.4 million in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Profit After Tax data on file, last reported at -$77.1 million in Q1 2026.
- Quarterly Profit After Tax fell 230.21% year-over-year to -$77.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$237.5 million (down 206.01% YoY) and the FY2025 annual result came in at -$183.8 million, down 69.12% from the prior year.
- Profit After Tax retreated to -$77.1 million in Q1 2026 per DFTX's latest filing, from -$50.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$4.9 million in Q4 2022 and bottomed at -$77.1 million in Q1 2026.
- The 5-year median for Profit After Tax is -$23.9 million (2023), against an average of -$30.7 million.
- The widest annual swing landed in 2024, when Profit After Tax jumped 79.9%; it then tumbled 630.17% in 2025.
- Tracing DFTX's Profit After Tax over 5 years: stood at -$4.9 million in 2022, then slumped by 386.72% to -$23.9 million in 2023, then slumped by 45.58% to -$34.7 million in 2024, then plunged by 45.18% to -$50.4 million in 2025, then sank by 52.86% to -$77.1 million in 2026.
- Per Business Quant, the three latest DFTX Profit After Tax figures stand at -$77.1 million (Q1 2026), -$50.4 million (Q4 2025), and -$67.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -77.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.10 Mn |
| Dec 31, 2025 | -50.44 Mn |
| Sep 30, 2025 | -67.27 Mn |
| Jun 30, 2025 | -42.74 Mn |
| Mar 31, 2025 | -23.35 Mn |
| Dec 31, 2024 | -34.74 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | -5.85 Mn |
| Mar 31, 2024 | -54.40 Mn |
| Dec 31, 2023 | -23.86 Mn |
| Sep 30, 2023 | -17.92 Mn |
| Jun 30, 2023 | -29.13 Mn |
| Mar 31, 2023 | -24.82 Mn |
| Dec 31, 2022 | -4.90 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.45 Mn |
| Dec 31, 2021 | -16.83 Mn |
| Sep 30, 2021 | -17.20 Mn |
| Jun 30, 2021 | -45.25 Mn |
| Mar 31, 2021 | -13.76 Mn |
| Dec 31, 2020 | -13.93 Mn |
| Sep 30, 2020 | -8.68 Mn |
| Jun 30, 2020 | -5.72 Mn |
| Mar 31, 2020 | -7.02 Mn |
| Dec 31, 2019 | -3.77 Mn |